RKIP Inhibition in Cervical Cancer Is Associated with Higher Tumor Aggressive Behavior and Resistance to Cisplatin Therapy

Olga Martinho1,2,3,*, Filipe Pinto1,2,*, Sara Granja1,2, Vera Miranda‐Gonçalves1,2, Marise A. R. Moreira4, Luís F. J. Ribeiro5, Celso di Loreto6, Marsha R. Rosner7, Adhemar Longatto‐Filho1,2,3,8, Rui Manuel Reis1,2,3,8

1 Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal, 2ICVS/IB/114549/2009 – PT Government Associate Laboratory, Braga/Guimarães, Portugal, 3 Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil, 4 Department of Pathology of the School of Medicine of the Federal University of Goias, Goiânia, Goiás, Brazil, 5 Hospital Araújo Jorge, Goiânia, Goiás, Brazil, 6 Pathology Division, Adolfo Lutz Institute São Paulo, São Paulo, Brazil, 7 Ben May Department for Cancer Research, University of Chicago, Chicago, Illinois, United States of America, 8 Laboratory of Medical Investigation (LIM) 14, Faculty of Medicine, São Paulo, São Paulo, Brazil

Abstract

Cervical cancer is one of the most common cancers in women worldwide, being high-risk group the HPV infected, the leading etiological factor. The raf kinase inhibitory protein (RKIP) has been associated with tumor progression and metastasis in several human neoplasms, however its role on cervical cancer is unclear. In the present study, 259 uterine cervix tissues, including cervicitis, cervical intraepithelial lesions and carcinomas, were analyzed for RKIP expression by immunohistochemistry. We found that RKIP expression was significantly decreased during malignant progression, being highly expressed in non‐neoplastic tissues (54% of the samples; 73/135), and expressed at low levels in the cervix invasive carcinomas (~15% (19/124)). Following in vitro downregulation of RKIP, we observed a viability and proliferative advantage of RKIP‐inhibited cells over time, which was associated with an altered cell cycle distribution and higher colony number in a colony formation assay. An in vitro wound healing assay showed that RKIP abrogation is associated with increased migratory capability. RKIP downregulation was also associated with an increased vascularization of the tumors in vivo using a CAM assay. Furthermore, RKIP inhibition induced cervical cancer cells apoptotic resistance to cisplatin treatment. In conclusion, we described that RKIP protein is significantly depleted during the malignant progression of cervical tumors. Despite the lack of association with patient clinical outcome, we demonstrate, in vitro and in vivo, that loss of RKIP expression can be one of the factors that are behind the aggressiveness, malignant progression and chemotherapy resistance of cervical cancer.

Citation: Martinho O, Pinto F, Granja S, Miranda‐Gonçalves V, Moreira MAR, et al. (2013) RKIP Inhibition in Cervical Cancer Is Associated with Higher Tumor Aggressive Behavior and Resistance to Cisplatin Therapy. PLoS ONE 8(3): e59104. doi:10.1371/journal.pone.0059104

Editor: Rossella Rota, Ospedale Pediatrico Bambino Gesù, Italy

Received November 23, 2012; Accepted February 11, 2013; Published March 19, 2013

Copyright: © 2013 Martinho et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was partially supported by the Portuguese Fundação para a Ciência e Tecnologia (grant PTDC/SAU-TOX/114549/2009). Olga Martinho and Sara Granja were recipients of PhD fellowships (SFRH/BD/36463/2007 and SFRH/BD/51062/2010, respectively), and Filipe Pinto and Vera Miranda‐Gonçalves were recipients of research fellowships (UMINHO/B/016/2011 and SFRH/B/33503/2008, respectively), both from FCT, Portugal. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.

Competing Interests: The authors have declared that no competing interests exist.

* E‐mail: reis@ecsaude.uminho.pt

These authors contributed equally to this work.

Introduction

Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause of cancer death in females worldwide, accounting for 9% of total cancer cases and 8% (275,100) of the total cancer deaths among females in 2008 [1]. Persistent infection with high‐risk types of human papillomavirus (HPV) is a sine‐qua‐non condition for cervical cancer development. HPV infect epithelial cells and cause a variety of lesions ranging from common warts to cervical neoplasia and cancer [2–4]. Tumors of the cervix are divided into three different histological subtypes: Uterine squamous cell carcinomas (SCC) is the most frequent, followed by adenocarcinoma (AC) and adenosquamous carcinoma (ASC), which is an uncommon subtype [5]. HPV infection alone is not enough for triggering cervical cancer and HPV‐mediated oncogenesis also requires the accumulation of additional genetic changes that occur over time following initial infection [6]. It may take several years for an in situ neoplasm to progress to an invasive carcinoma. The mechanism of clonal evolution, which involves the selection of cells with invasive or metastatic potential, also remains unsolved.

Raf kinase inhibitory protein (RKIP; also known as PEBP1, for phosphatidylethanolamine‐binding protein1), as indicated by the name, was first identified as the endogenous inhibitor of the RAF/MEK/ERK pathway, inhibiting Raf‐1 activation [7–9]. Actually, RKIP has been implicated in various intracellular signaling pathways that control cell growth [10,11], motility [12,13], epithelial to mesenchymal transition (EMT) [14] and differentia-
tion [15]. RKIP is widely expressed in normal human tissues, highlighting its role in various physiological processes [16], but is considered to be a metastasis suppressor in cancer [17], being its loss or reduced expression associated with malignancy and prognosis in many types of metastatic and aggressive cancers [10,11,18–34].

A previous study, done in a small fraction of patients, found by expression microarray analysis that RKIP is one of the genes that is differentially expressed between tumor samples from cervical cancer patients with or without lymph node metastasis [35]. More recently, it was found in a large series of patients that RKIP protein is significantly downregulated in cervical cancer and lymph node metastasis [36]. Additionally, another study with HeLa cervical cancer cells showed that RKIP, through regulation of the ERK pathway, has an important role in mitotic checkpoint regulation [37]. Hence, the previous findings, prompted us to elucidate the biological role of RKIP in cervical cancer malignant progression and chemotherapy response. Therefore, we first assessed the expression levels of RKIP protein in both non-malignant and tumoral cervical samples, and assessed its role in the clinical outcome of cervical cancer patients. Secondly, we assessed in vitro and in vivo the biological function of RKIP downregulation in cervical cancer malignancy and chemotherapy response.

Materials and Methods

Tissue Samples

For the present work, 259 cervical tissues were analyzed, which included 45 cervicitis, 47 low-grade squamous intraepithelial lesions (LSIL), 43 high-grade squamous intraepithelial lesions (HSIL), 70 squamous cell carcinomas (SCC), 41 adenocarcinomas (AC) and 13 adenosquamous carcinomas (ASC) (Table 1). The paraffin samples containing the cervical non-malignant lesions were retrieved from the files of the Pathology division of Adolfo Lutz Institute São Paulo, Brazil, and the invasive cervical tumor samples were retrieved from Araújo Jorge Hospital and School of Medicine of the Federal University of Goiás (Goiânia, Goias State, Brazil). All histopathological diagnoses were reviewed by the authors and categorized according to the WHO classification. All patients with cervical cancer were females of Brazilian origin, with a mean age of 49 years (range 23–74 years). Follow-up data was available for 72 patients, and collected through direct interview with patients or their relatives, and by review of in-hospital patient files. The median follow-up time (overall survival) was 35.5±42.0 months (range, 2–144 months).

All the samples enrolled in the present study were unlinked and unidentified from their donors. Due the retrospective nature of the study, no written informed consent from patients was obtained. The Local Ethical Review Committees of the involved institutions (Ethics committee in Human Research of Adolfo Lutz Institute São Paulo and of Araújo Jorge Hospital from School of Medicine of the Federal University of Goiás, Brazil) approved the work and waived the need for written informed consent.

Cell Lines

For the present study it were used three cervical carcinoma cell lines: HeLa cell line, kindly provided by Dr Elisa Logarinho (IBMC, Portugal) [38], SiHa and C-33A cell lines that were kindly provided by Dr Luisa Villa (INCT-HPV, Brazil) [39]. All the cell lines were grown and maintained at 37°C and 5% CO₂ in Dulbecco’s Modified Eagle’s Medium (DMEM) 1×, High Glucose; Gibco, Invitrogen) supplemented with 10% Fetal Bovine Serum (FBS; Gibco, Invitrogen) and 1% penicillin/streptomycin solution (Gibco, Invitrogen) [DMEM-10].

| Type of Lesion | N | Negative (%) | Positive (%) | p  |
|---------------|---|--------------|--------------|----|
| Cervicitis    | 45 | 16 (35.6) | 29 (64.5) |     |
| LSIL          | CIN1 | 47 | 26 (55.3) | 21 (44.7) |     |
| HSIL          | CIN2 | 16 | 6 (37.5) | 10 (62.5) |     |
|              | CIN3 | 27 | 14 (51.9) | 13 (48.1) |     |
| LSIL          | 47 | 26 (55.3) | 21 (44.7) | 0.404 |
| HSIL          | 43 | 20 (46.5) | 23 (53.5) |     |
| Invasive Carcinoma | AC | 40 | 33 (80.5) | 8 (19.5) | 0.643 |
|              | SCC | 70 | 61 (87.1) | 9 (12.9) |     |
|              | ASC | 13 | 11 (84.6) | 2 (15.4) |     |
| Cervicitis    | 45 | 16 (35.6) | 29 (64.5) | 0.087 |
| Sil           | 90 | 46 (51.1) | 44 (48.9) |     |
| Benign Lesions | 135 | 62 (46.0) | 73 (54.0) | <0.001 |
| Cervical Cancer | 124 | 105 (84.7) | 19 (15.3) |     |

Cervical intraepithelial neoplasia (CIN); Low-grade squamous intraepithelial lesions (LSIL); high-grade squamous intraepithelial lesions (HSIL); squamous cell carcinomas (SCC); adenocarcinomas (AC); adenosquamous carcinomas (ASC). doi:10.1371/journal.pone.0059104.t001

Drugs

Cisplatin (cis-Diammineplatinum(II) dichloride) was obtained from Sigma-Aldrich and diluted in 0.9% NaCl for a stock solution of 10 mM. The drug was subsequently prepared as intermediated dilutions to obtain an equal quantity of drug vehicle (1% final concentration) in each of the conditions studied. In all experimental conditions the drugs were diluted in 0.5% FBS culture medium (DMEM-0.5).

Immunohistochemistry and Immunocytochemistry Analysis of RKIP

Histological slides with 4 μm-thick tissue sections were subjected to immunohistochemical analysis according to the streptavidin-biotin peroxidase complex system (UltraVision Large Volume Detection System Antipolyvalent, HRP; LabVision Corporation), using the primary antibody raised against RKIP (Millipore, reference 07–137) diluted 1:600, incubation 1H at RT, as previously described [18,25,40,41].

Sections were scored double-blind for cytoplasmatic expression following a semi-quantitative criterion: (−), 0% of immunoreactive cells; (+), <5% of immunoreactive cells; (++), 5–50% of immunoreactive cells; and (+++), >50% of immunoreactive cells. Samples with scores (−) and (+) were considered negative, and those with scores (+++) and (+++) were considered positive. For RKIP immunocytochemical analysis of cervical carcinoma cell lines, the cells were plated on glass coverslips placed into 12-well plates, and allowed to adhere overnight. The immunocytochemistry procedure was performed as previously described [41].
Generation of shRKIP Stably Expressing Cell Lines

For generation of cell lines stably expressing shRKIP, we used the PQY15 vector, containing a 19 bp shRNA for RKIP, as previously described [37,41,42]. The transfection was done by using the FUGENE HD reagent (Roche) as recommended by the manufacturer, with 2 μg of plasmid at a ratio of 6:2 (Reagent:-Plasmid). The cells (2 × 10⁶) were plated onto a 12-well plate until 90% of confluence and transfected in DMEM medium, without FBS or antibiotics addition, during 24 hours [41]. After that, stable transfectants were selected with 0.5 μg/ml (HeLa) or 2 μg/ml (C-33A and SiHa) of puromycin in DMEM-10. The empty vector was also transfected as a control.

Western Blot Analysis

The cells were plate in a 6 well plate at a density of 8 × 10⁵ cells per well and allowed to adhere at least 24 hours. The cells were serum starved for 6 hours before protein isolation. When necessary, the cells were also stimulated with 10 ng/ml of EGF by 10 minutes before the end of the 6 hours of starvation. Also, for cisplatin experiments the cells were exposed to various concentrations of cisplatin for an additional period of 24 hours in DMEM-0.5. The cells were scraped in cold PBS and lysed in buffer containing 50 mM Tris pH 7.6–8, 150 mM NaCl, 5 mM EDTA, 1 mM Na₃VO₄, 10 mM NaF, 10 mM NaPyrophosphate, buffer containing 50 mM Tris pH 7.6–8, 150 mM NaCl, 5 mM EDTA, 1 mM Na₃VO₄, 10 mM NaF, 10 mM NaPyrophosphate, 1% NP-40 and 1/7 of Protease cocktail inhibitors (Roche). The cells were also transfected as a control.

To determine the concentration at which 50% of the cell growth is inhibited by cisplatin treatment (IC₅₀ concentration), the cells were plated into 96-well plates at a density of 3 × 10⁴ to 5 × 10⁴ cells per well and allowed to adhere overnight in DMEM-10. Subsequently, the cells were treated with increasing concentrations of the drug diluted in DMEM-0.5. After 48 hours, cell viability was quantified using Cell Titer96 Aqueous cell proliferation assay (MTS) (Promega). The results were expressed as mean ± SD viable cells relatively to drug vehicle alone (considered as 100% viability). The IC₅₀ concentration was calculated by nonlinear regression analysis using GraphPad Prism software.

Wound Healing Migration Assay

The cells were seeded in 6-well plates and cultured to at least 95% of confluence. Monolayer cells were washed with PBS and scraped with a plastic 200 μl pipette tip and then incubated with fresh DMEM medium without serum. The “wounded” areas were photographed by phase contrast microscopy at 12, 24 or 48 hours' time points. The relative migration distance was calculated by the following formula: percentage of wound closure (\(\%\)) = 100 (A-B)/A, where A is the width of cell wounds before incubation, and B is the width of cell wounds after incubation [41]. Results are expressed as the mean ± SD. The assay was done in triplicate at least three times.

Cell Cycle Analysis

The cells were plated in a 6-well plate at a density of 2 × 10⁵ cells per well and allowed to adhere overnight. After 6 hours of serum starvation the cells were incubated with fresh DMEM medium without serum during 24 hours. Cells were trypsinized and fixed in 70% ethanol at least 30 minutes and then stained during 1 hour at 50°C with a propidium iodide (PI) solution (20 μg/mL of PI and 250 μg/mL of RNAse in a solution of 0.1% Triton X-100 in PBS). Cell cycle analysis of the PI stained cells was performed by flow cytometry (LSRII, BD Biosciences). The percentage of cells in each phase of the cell cycle was determined with the software FlowJo version 7.6.3. The results were expressed as the mean ± SD of the percentage of cells in G1 phase or G2/M phase S phase [41]. The assay was done in triplicate at least three times.

Soft Agar Colony Formation Assay

The soft-agar colony formation assay was done using standard methods, as previously described by us [43]. Briefly, 1 mL underlayers (base agar layers) consisting of 0.6% agar medium were prepared in 6-well plates by combining equal volumes of 1.2% Noble agar with either 2 × DMEM medium with 20% FBS. The cells were trypsinized, centrifuged, and resuspended in 0.35% agar medium (top agar layer; equal volumes of 0.7% Noble agar and 2 × DMEM with 20% FBS). 2 × 10⁵ cells were then plated onto the previously prepared base agar layers. The cells were incubated at 37°C in a humidified 5% CO₂ atmosphere for 15 days and the colonies formed stained with 0.05% violet crystal for 15 minutes. Stained colonies were photographed using a stereomicroscope (Olympus SZX16) and a digital camera (Olympus DP71) and counted with ImageJ Software. Only colonies with a size greater than 775 μm² (approximately 31.4 μm of diameter) were counted [43]. Results are expressed as the mean ± SD. The assay was done in triplicate at least three times.

Chick Chorioallantoic Membrane (CAM) Assay

To assess in vivo tumor proliferation and angiogenesis we used the CAM assay as previously described [41,43]. Fertilized chicken eggs were incubated at 37°C and 70% humidity, and on day 3 of...
development, a window was made into the shell, which was sealed with tape, and the eggs were returned to the incubator. On day 9 of development, small plastic rings were placed on the CAM and on day 10 of development 3×10⁵ cells, resuspended in 20 μl of DMEM medium, were injected in the rings over the CAM. On day 17 of development, the tumor formed was photographed in vivo using a stereomicroscope (Olympus S2×16), and the perimeter of the tumor was measured using Cell B software (Olympus). Results are expressed as the mean ± SD.

Finally, the chicken eggs were sacrificed at −80°C for 10 minutes, and CAM and tumors were fixed with paraformaldehyde at 4% and photographed ex vivo for blood vessels counting. The tumors were embedded in paraffin and processed for histological analysis.

**Statistical Analysis**

Correlations between RKIP expression and clinical data from patients were performed using the chi-square test (χ²-test). Cumulative survival probabilities were calculated using the Kaplan-Meier method. Differences between survival rates were tested with the log-rank test. The statistical analysis was performed using SPSS software for Windows, version 17.0. For in vitro and in vivo assays, single comparisons between the different conditions studied were done using Student’s t test, and differences between groups were tested using two-way analysis of variance (ANOVA). Statistical analysis was done using Graph Pad Prism version 5. The level of significance in all the statistical analysis was set at p<0.05.

**Results**

**RKIP Expression in Cervical Tissues**

An immunohistochemistry approach was done to detect RKIP protein expression and distribution in cervical lesions (Fig. 1).

Cytoplasmatic positive expression of RKIP was observed in 64.5% (29/45) of the cervicitis samples, in 44.7% (21/47) of LSIL and 53.5% (23/43) of HSIL (Table 1) (Fig. 1A and B). No significant differences were observed in the expression levels of RKIP between LSIL and HSIL (p = 0.404), and also between cervicitis and squamous intraepithelial lesions (SIL) in general (p = 0.087), Table 1. Concerning malignant lesions, RKIP was present at low levels, with only 19.5% (8/41) of AG, 12.9% (9/70) of SCC and 15.4% (2/13) of ASC depicting positive staining (Table 1) (Fig. 1C and D). No significant differences were observed between RKIP expression in the different malignant lesions studied (p = 0.643, Table 1). However, when grouping the benign lesions (cervicitis and SIL) and the malignant lesions (AG, SCC and ASC), a statistical significant decrease of RKIP expression was observed in cervical cancer samples (p<0.001) when compared with the benign lesions (Table 1).

No correlations were found between RKIP expression and clinical features of patients, such as age, presence of metastasis and follow-up data, independently of the histological type (p>0.05, Table 2).

**RKIP Expression and Modulation of ERK Pathway in Cervical Cancer Cell Lines**

To study the role of RKIP in cervical cancer, we first screened for RKIP expression in human cervical cancer cell lines (HeLa, SiHa and C-33A) by immunocytochemistry and western blot (Fig. 2). We found that RKIP is expressed at high levels in all cell lines, and is present at both cytoplasm and nucleus of the cells (Fig. 2A), as already described before [37]. All the cell lines were used to knockdown the expression of RKIP by stable transfection with PQY15 vector containing a short hairpin-RNA for RKIP (shRKIP). The empty vector was also transfected as control. The RKIP protein levels in these stable transfected cells were determined by western blot analysis. As shown in Fig. 2B, RKIP protein levels was efficiently inhibited in the shRKIP transfected cells when compared to the empty vector transfected cells.

To explore the role of RKIP in the modulation of EGF stimulated ERK signaling in cervical cancer, the transfected cells were stimulated with EGF, and EGFR and ERK phosphorylation levels were assessed by western blot. As it can be observed in Fig. 2B, EGF stimulation did not result in significant effects in the activation of ERK signaling in these cells, independently of RKIP status.

**Role of RKIP Expression in Cervical Cancer Cell Lines**

**Biological Behavior**

To assess whether the modulation of RKIP expression influenced the tumorigenic properties of the cells, we chose the cell line with highest level of RKIP inhibition by shRKIP, HeLa and measured in vitro its viability, proliferation, anchorage independent growth and migration capabilities (Fig. 3). We observed that shRKIP transfected cells have a significant viability advantage over time (Fig. 3A), when compared with the empty vector transfected cells (p<0.05). This difference may be a reflection of an increased cell number or it may reflect increased cellular metabolism. To see whether this viability advantage was due to higher proliferation rates, we studied the effect of RKIP on BrdU incorporation, cell cycle distribution and anchorage-independent growth. The BrdU assay, confirmed that shRKIP transfected cells have a significant proliferative advantage over time (Fig. 3B). The soft agar colony formation assay demonstrated a significant (p<0.05) increase in the number of the colonies formed in the shRKIP transfected cells when compared to the control cells (Fig. 3C). By cell cycle analysis, we observed that shRKIP transfected cells had a decreased G0/G1 phase with a concomitant and significant (p<0.05) increase in the G2/M phase (Fig. 3D). These results were further validated in the other two transfected cell lines, SiHa and C-33A (Fig. S1A–D).

Finally, to address the effect of RKIP in HeLa cells migration, we performed wound healing migration assay and observed that shRKIP transfected cells had a migration advantage over time, with a significant (p<0.05) higher rate of wound closure when compared with the control cells (Fig. 3E). The same was observed in the other two transfected cell lines, SiHa and C-33A (Fig. S1E–F).

**In vivo Role of RKIP Expression in Cervical Cancer Growth and Angiogenesis**

To examine the effect of RKIP-mediated tumor growth and angiogenesis in vivo, we performed the CAM assay (Fig. 4). The transfected cells were implanted into the CAM of the chick embryo (empty vector cells, n = 10; shRKIP cells, n = 10), and seven days after cell implantation, the chicken embryos were sacrificed to evaluate tumor growth and angiogenesis, as described in materials and methods section. The mean perimeter of the tumors formed by the control and the shRKIP transfected cells was 4335±283 mm and 4913±1568 mm, respectively. As shown in Fig. 4B, the size of the tumors formed by shRKIP cells was not significantly higher when compared to the tumors formed by the empty vector cells.

To evaluate the impact of RKIP in angiogenesis modulation, we counted ex vivo the number of vessels around the tumors. We counted a mean of 54±16 and 83±10 vessels in the tumors formed by the empty vector and the shRKIP transfected cells,
respectively. RKIP inhibited cells revealed a statistically significant ($p<0.05$) increase in blood vessels recruitment when compared to the control cells (Fig. 4D). As shown in Fig. 4C, the hematoxylin-eosin staining of the paraffin embedded tumors and CAMs confirmed the rich vascularization of the tumors with capillaries around the tumor and capillaries sprouting out of the CAM into the tumors. Higher rates of vascularization were observed in the tumors formed by shRKIP transfected cells (Fig. 4C).

### Role of RKIP Protein in Cervical Cancer Cells Response to Chemotherapy

To determine whether RKIP protein could be involved in the modulation of cervical cancer patient’s response to the conventional chemotherapy, we determined the sensibility of cervical cancer cell lines transfected with shRKIP to cisplatin treatment. As it can be observed in the cytotoxic assays (Fig. 5A), all the shRKIP transfected cell lines were less sensitive to cisplatin treatment, when compared to the control cell lines transfected with the empty vector, being this difference less evident for C-33A cell line. As shown in Fig. 5B, HeLa cells transfected with the shRKIP displayed a mean $IC_{50}$ of $18.55\pm 2.06\, \mu M$ against the $5.91\pm 0.30\, \mu M$ reached by the empty vector cells. For C-33A cell line the values were more similar between the two transfected cell lines, $10.37\pm 2.69\, \mu M$ and $13.25\pm 1.98\, \mu M$ for the empty vector and the shRKIP transfected cells, respectively (Fig. 5B). The SiHa

#### Table 2. Correlations between RKIP expression and cervical cancer patient's clinical data.

| Parameter          | N    | RKIP Expression |
|--------------------|------|-----------------|
|                    |      | Negative (%)    | Positive (%) | $p$  |
| Age (years)        |      |                 |              | 0.805 |
| $>49$              | 15   | 12 (80)         | 3 (20)       |      |
| $\leq 49$          | 18   | 15 (83.3)       | 3 (16.7)     |      |
| Metastasis*        |      |                 |              | 0.728 |
| Absent             | 48   | 42 (87.5)       | 6 (12.5)     |      |
| Lymph node         | 5    | 4 (80.0)        | 1 (20.0)     | 0.038 |
| Distant            | 14   | 13 (92.9)       | 1 (7.1)      |      |
| Follow-up (months ± SD) | 72   | 123.6±6.8       | 95.4±10.9    | 0.938 |

*Log-rank test determined by Kaplan-Meier method.

doi:10.1371/journal.pone.0059104.t002

doi:10.1371/journal.pone.0059104.g001

**Figure 1. Immunohistochemistry analysis of RKIP in cervical tissues.**

A) Positive expression in a cervicitis. B) High-grade squamous intraepithelial lesion with negative expression. C) Adenocarcinoma tissue depicting positive expression. D) Negative adenocarcinoma (*) with adjacent normal cells (arrow) depicting positive staining. All the pictures were taken with at 200× magnification.

The figures demonstrate the differential expression of RKIP in cervical tissues, indicating its potential role in the development and progression of cervical cancer.
cell line was the less sensitive to cisplatin with the empty vector transfected cells reaching $25.99 \pm 0.51 \mu M$ of mean IC$_{50}$, while the shRKIP transfected cells reached $40.69 \pm 2.37 \mu M$ of mean IC$_{50}$ for cisplatin (Fig. 5B).

To explore the mechanisms by which RKIP induces resistance to cisplatin in cervical cancer cell lines, we exposed HeLa cells to increasing concentrations of cisplatin during 24 hours (Fig. 5C), and found that cisplatin treatment induced ERK activation in both cell lines, more evident for higher doses, but shRKIP transfected cells were more resistant to cisplatin induced PARP and capase-9 cleavage (Fig. 5C). Thus, RKIP seems to modulate cervical cancer cells response to cisplatin chemotherapy by controlling apoptosis.

**Discussion**

The role played by HPV in cervical cancer initiation is well known; however, the molecular pathways involved in the progression and metastasization processes remains unclear [6].

While the broad use of Papanicolaou smear screening has led to a decline in mortality from cervical cancer, many patients still died of the disease, mainly due to cancer metastasis [44]. Therefore, it is important to elucidate the mechanisms involved in cervical cancer aggressiveness and metastatisation.

In cancer, RKIP is considered to be a metastasis suppressor gene, being downregulated during the metastatic process of distinct tumors [18,20–23]. In the present study, we studied the protein expression levels of RKIP not only in cervical cancer, but also in non-malignant lesions (cervicitis and intraepithelial lesions). In general, we found that RKIP is highly expressed at the cytoplasm in the benign lesions (54% of the samples; 73/135), but is significantly ($p < 0.05$) reduced in cervical cancer (independently of the histological subtype), with only $\sim15\%$ (19/124) of the samples staining positively. No associations were found between RKIP expression and the presence of metastasis. Also, no correlations were found between the remaining patient’s clinico-pathological data or survival, which limits its use as prognostic marker. However, further studies, involving a larger number of
Figure 3. In vitro role of RKIP in HeLa cells biological behavior. A) Cellular viability and B) Proliferation was measured at 24, 48 and 72 hours by MTS and BrdU assays, respectively. RKIP inhibited cells had a statistically significant viability and proliferative advantage over time, when compared to control cells. C) Cells were assayed for their ability to proliferate in growth medium containing 0.35% agar and the formation of multicellular colonies photographed at x16 magnification after 14 days. RKIP inhibition induces a statistically significant anchorage-independent growth of HeLa cells in soft agar. D) Downregulation of RKIP in HeLa cells induced a shift on cell cycle distribution with a statistically significant higher percentage of cells in G2M+S phase when compared to control cells. Cell cycle analysis was done at 24 hours' time point by flow cytometric analysis of propidium iodide stained cells. E) A standardized scratch (wound) was applied to monolayers and digital images were taken at several time points.
patients with a more comprehensive clinicopathological data available, are needed to validate and extend our findings. Additionally, it would be interesting to analyze the interplay between RKIP and HPV infection. Hu CJ and colleagues have recently reported results very similar to ours: the high expression of RKIP in non-tumoral or pre-malignant lesions, and its significant

(0; 12; 24 and 48 hours). It was observed that shRKIP transfected cells had a statistically significant migration advantage over time, when compared to control cells (right panel). Representative images at 0 and 48 hours are presented in the left panel. All the experiments were done in triplicate at least three times. Data is represented as the mean ± SD and differences with a p<0.05 on the two-way ANOVA or student’s t test were considered statistically significant (*).

doi:10.1371/journal.pone.0059104.g003

Figure 4. In vivo role of RKIP in HeLa cells growth and angiogenesis. A) Representative pictures (16× magnification) of CAM assay after 7 days of tumor growth in ovo and ex ovo. B) Tumor growth was measured in vivo by CAM assay as described in materials and methods section. It was observed a higher perimeter (μM) of the tumors (in ovo) formed by shRKIP cells, however the difference between the control cells was not significant. C) Hematoxylin-eosin staining of the paraffin embedded tumors showing the higher vascularization induced by RKIP inhibition. Representative pictures with 10× and 20× magnification are represented in the left panel. D) Counting of the blood vessels ex ovo, it was observed a statistically significant increase on the number of vessels recruited in the tumors formed by shRKIP cells when compared to the control. In total it was analyzed 20 eggs (10 were injected with empty vector and 10 with shRKIP cells). The data is represented as the mean ± SD and differences with a p<0.05 on the Student’s t test were considered statistically significant (*).

doi:10.1371/journal.pone.0059104.g004
lost in primary tumors of the cervix and in its lymph node metastases. Similar to us, the authors did not found significant correlation between RKIP positivity and clinical outcome [36]. In many other studies, loss of RKIP protein has been associated with poor prognosis [18,22,25–28,30,33,34], but at variance, many studies, including ours, have come out showing the absence of RKIP in primary tumors independently of associations with presence of tumor metastasis or prognosis [10,11,24,28,31,32,45,46].

RKIP action was first described as an inhibitor of the RAF-1-MEK interaction, thereby preventing the activation of RAF/MEK/ERK signal transduction [8]. Recently, several studies have showed that RKIP is involved in more intracellular signaling pathways. Stimulation of cells with a growth factor, such as EGF, induces RKIP phosphorylation at S153 by protein kinase C reduces the affinity of RKIP for c-RAF and enhances RKIP binding to G-protein–coupled receptor kinase-2 [7,47]. Moreover, RKIP suppresses the activation of the nuclear factor Kappa B (NFkB) cell survival pathway by blocking the inactivation of the inhibitor of NFkB, namely IκB [48]. More recently, it was shown that RKIP binds GSK3 proteins and maintains GSK3β protein levels and its active form [49]. The involvement of RKIP in signal transduction pathways that are important regulators of growth, motility, invasion and differentiation in cancer cells, re-enforce the usefulness of functional studies to assess its role in tumors where its expression is downregulated.

To understand the biological role of the reduction of RKIP in cervical cancer specimens, we performed in vitro and in vivo studies with three distinct cervical cancer cell lines. RKIP downregulation was done by cells transfection with a specific shRNA for RKIP, which resulted in the reduction of the protein levels, as already described [37,50].

Firstly, we studied the role of RKIP in the control of cervical cancer cells growth. We observed that cells with low levels of RKIP had in vitro a viability advantage over time when compared with cells with normal levels of RKIP. This viability advantage was shown to be due to the high levels of proliferation of the cells, as evidenced by BrdU and colony formation assays, which is probably promoted by a shift in cell cycle distribution with a higher percentage of cells in G2/M and S phase. The in vitro effect of RKIP in cellular proliferation and cell cycle regulation has not been consistent in the literature, and this may reflect in part the assays used. Our data agrees with those of Li et al who obtained similar results in ovarian cancer cell lines with regard to viability and anchorage-independent growth [45]. Also, Lee et al found that the proliferation of human hepatoma cells was reduced in cells

Figure 5. Role of RKIP in cervical cancer cells response to cisplatin. A) Representative pictures of the nonlinear regression analysis of cervical cancer cell lines treated with cisplatin for determination of half maximal inhibitory concentrations (IC50). B) Graphic representation of the mean IC50 values for cisplatin in the cervical cancer cell lines. The transfected cells with shRKIP were less sensitive to cisplatin treatment in the three different cell lines. C) HeLa transfected cell lines were exposed to increasing concentrations of cisplatin by 24 hours. Cisplatin treatment induced ERK activation (p-ERK1/2) and apoptosis of the cells as evaluated by PARP (total and cleaved specific antibodies) and caspase-9 cleavage, mainly in the empty vector transfected cells. All the experiments were done in triplicate at least three times. Data in the panels A and B are represented as the mean ± SD. doi:10.1371/journal.pone.0059104.g005
overexpressing RKIP [51]. However, Schuierer et al reported that RKIP did not influence melanoma cell proliferation in vitro [52], an observation that was also supported using prostate cells [20]. Regarding cell cycle, our results were similar to those obtained by other authors in ovarian and nasopharyngeal carcinomas [45,53]. However, previous studies with HeLa cells showed a change in mitotic index but no significant change in cell proliferation [37].

In vivo, we did not observe differences in the size of the tumors formed by RKIP inhibited cells when compared to control cells, consistent with results from mouse xenograft models [19]. Dangi-Garimella et al demonstrated that RKIP regulates invasion, intravasation and metastasis in human breast cancer but does not significantly alter primary tumor growth in vivo, consistent with a role as a metastasis suppressor [19]. Thus, the discrepant in vitro and in vivo findings suggest that RKIP function can be influenced by the tumor microenvironment.

To explore the putative role of RKIP in the regulation of cervical cancer metastasis, we studied the migratory and angiogenic properties of RKIP downregulated cells. We found in vitro that the absence of RKIP is related with higher migratory capability of the cells, and in vivo that tumors formed by injection of shRKIP cells were significantly more vascularized. Similar results using wound healing migration assay were already obtained with other cell types, such as kidney, fibroblasts and hepatoma cells [12,50,51]. Concerning angiogenesis, our results are in agreement with the results reported by Li et al, who reported the low expression of RKIP associated with angiogenesis in a breast cancer mouse model [54]. Likewise, Fu et al reported that overexpression of RKIP reduces the angiogenic capacity and vascular invasion in a prostate mouse model [20], this being a crucial mechanism through which RKIP regulates metastasis.

Importantly, we observed a clear apoptotic resistance of cervical cancer cells to cisplatin treatment associated with low levels of RKIP expression. Other studies have shown that RKIP is also involved in the regulation of tumor cells response to both radio and chemotherapy. In drug-sensitive cell lines, down-regulation of RKIP led to the resistance to DNA-damaging drugs (9-nitrocamptothecin, taxol and cisplatin) [55]. Loss of RKIP expression in cancers leads to transcriptional activation of NFkB and other authors in ovarian and nasopharyngeal carcinomas [45,53]. However, previous studies with HeLa cells showed a change in mitotic index but no significant change in cell proliferation [37].

In contrast, no effects were observed in the tumors growth in vivo, but it was found that RKIP inhibition is associated with higher angiogenic rates in cervical cancer. Furthermore, we observed that RKIP expression has an impact on cervical cells effective response to cisplatin treatment. Altogether, our results would indicate RKIP as a potential biomarker for cervical cancer patients.

Supporting Information

Figure S1 In vitro role of RKIP in SiHa and C-33A cells biological behavior. A–B) Cellular viability was measured by MTS. RKIP inhibited cells had a statistically significant viability advantage over time, when compared to control cells. C–D) Cells were assayed for their ability to proliferate in growth medium containing 0.35% agar and the formation of multi-cellular colonies were assayed for their ability to proliferate in growth medium containing 0.35% agar and the formation of multi-cellular colonies were assayed for their ability to proliferate in growth medium containing 0.35% agar and the formation of multi-cellular colonies were assayed for their ability to proliferate in growth medium containing 0.35% agar and the formation of multi-cellular colonies were assayed for their ability to proliferate in growth medium containing 0.35% agar and the formation of multi-cellular colonies were assayed for their ability to proliferate in growth medium containing 0.35% agar and the formation of multi-cellular colonies were assayed for their ability to proliferate in growth medium containing 0.35% agar and the formation of multi-cellular colonies photographed at x16 magnification after 14 days. RKIP inhibition induces a statistically significant anchorage-independent growth in soft agar. E–F) A standardized scratch (wound) was applied to monolayers and digital images were taken at several time points. It was observed that shRKIP transfected cells had a statistically significant migration advantage over time, when compared to control cells. All the experiments were done in triplicate at least three times. Data is represented as the mean ± SD and differences with a p<0.05 on the two-way ANOVA or student’s t test were considered statistically significant [*]. (TIF)

Author Contributions

Data interpretation, generation of figures: OM FP. Collected the cases and clinical data: MARM LFJR CL. Evaluated the immunohistochemistry reactions: ALF. Provided the plasmids and participated in data analysis, interpretation and revision of the manuscript: MR. Was responsible for study concept and design, study supervision, and critical revision of the manuscript: RMR. Involved in revision of the paper and had final approval of the submitted and published versions: OM FP SG VMG MARM LFJR CL MR ALF RMR. Performed the experiments: OM FP SG VMG. Analyzed the data: OM FP. Wrote the paper: OM FP.
18. Martinho O, Simões K, Longatto-Filho A, Jacob CE, Zilberstein B, et al. (2013) Role of RKIP in cell motility. Chem Biol 12: 953–954.

11. Zhang L, Fu Z, Binkley C, Giordano T, Burant CF, et al. (2004) Raf kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol. Biosyst 7: 928–941. 10.1039/b700239g [doi]

10. Akaishi J, Onda M, Asaka S, Okamoto J, Miyamoto S, et al. (2006) Growth-inhibitory protein inhibits beta-cell proliferation. Surgery 136: 708–715. 10.1016/j.m corresponding to poor prognosis in HCC related to hepatitis B infection. J Hepatol 49: 258–264. 10.1016/j.jhep.2008.06.039 [pii];10.1016/j.jhep.2008.06.039 [doi]

9. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, et al. (2000) Raf-1 kinase inhibitory protein suppresses a metastasis signalling cascade involving extracellular signal-regulated kinase and RKIP. J Clin Pathol 71: 658–663. 10.1136/jcp.71.8.658 [pii];10.1136/jcp.71.8.658 [doi]

8. Eves EM, Shapiro P, Naik K, Klein UR, Trakul N, et al. (2006) Raf kinase inhibitory protein regulates Snail expression during chromosome alignment. Nat Cell Biol 8: 291–297. 10.1038/ncl20022 [pii];10.1038/ncl20022 [doi]

7. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK (2004) Reduction of Raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol 122: 820–827. 10.1309/ACP-00841 [pii];10.1309/ACP-00841 [doi]

6. Kim HS, Kim GY, Lim SJ, Kim YW (2010) Loss of Raf-1 kinase inhibitory protein expression in thyroid carcinomas. Endocr Pathol 21: 253–257. 10.1097/MD.0b013e3181f3f74e [pii];10.1097/MD.0b013e3181f3f74e [doi]

5. Zaravinos A, Chatzianastassiou M, Lambrou GI, Boulalis I, Delakas D, et al. (2010) Implication of Raf and RKIP Genes in Urothelial Bladder Cancer. Pathol Oncol Res. 16: 1–9. 10.1007/s12016-009-0076-x [pii];10.1007/s12016-009-0076-x [doi]

4. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, et al. (2004) RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279: 1541–7786.MCR-08–0403 [doi].

3. Mirowski P, Zlobec I, Terracciano L, et al. (2007) Loss of Raf-1 kinase inhibitory protein expression is associated with tumor progression and metastasis in colorectal cancer. Cancer Res 67: 5633–5640. 10.1158/0008–5472.CAN-06–2441 [pii];10.1158/0008–5472.CAN-06–2441 [doi]

2. Martinho O, Faloppa CC, Scapulatempo NC, Longatto-Filho A, Baiocchi G, et al. (2010) Raf kinase inhibitor protein enhances neuronal differentiation in human SH-SY5Y cells. Dev Neurosci 32: 33–46. 10.1007/s00791-009-2252-x [pii];10.1007/s00791-009-2252-x [doi]

1. Keller ET, Fu Z, Brennan M (2004) The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem Pharmacol 68: 1049–1053. 10.1016/j.bcp.2004.02.012 [pii];S0006-2952(04)00360-0 [pii].

PLOS ONE | www.plosone.org 11 March 2013 | Volume 8 | Issue 3 | e59104

Role of RKIP Protein in Cervical Cancer
58. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, et al. (2004) RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279: 17515–17523. 10.1074/jbc.M313816200 [doi]; M313816200 [pii].
59. Al-Mulla F, Bitar MS, Feng J, Park S, Yeung KC. (2012) A new model for raf kinase inhibitory protein induced chemotherapeutic resistance. PLoS One 7: e29532. 10.1371/journal.pone.0029532 [doi]; PONE-D-11-09100 [pii].
60. Zhu S, Mc Henry KT, Lane WS, Fenteany G. (2003) A chemical inhibitor reveals the role of Raf kinase inhibitor protein in cell migration. Chem Biol 12: 981–991.
61. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. (2004) Inhibition of the Raf/MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin’s lymphoma B cells by Rituximab. Cancer Res 64: 7117–7126.
62. Bonavida B, Barzaki S, Huerta-Yepez S, Vega MI, Chatterjee D, et al. (2008) Novel therapeutic applications of nitric oxide donors in cancer: roles in chemosensitization to apoptosis and inhibition of metastases. Nitric Oxide 19: 152–157.